Check out these key findings about Gracell Biotechnologies Inc. (GRCL)

Gracell Biotechnologies Inc. (NASDAQ: GRCL) stock fell -3.30% on Thursday to $2.64 against a previous-day closing price of $2.73. With 87589.0 shares changed hands, the volume of the stock remained lighter than its average volume of 0.1 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.8350 whereas the lowest price it dropped to was $2.5200. The 52-week range on GRCL shows that it touched its highest point at $5.69 and its lowest point at $1.40 during that stretch. It currently has a 1-year price target of $12.57.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of GRCL was up-trending over the past week, with a rise of 21.66%, but this was up by 80.82% over a month. Three-month performance surged to 32.00% while six-month performance fell -24.57%. The stock lost -14.84% in the past year, while it has gained 14.78% so far this year. A look at the trailing 12-month EPS for GRCL yields -1.28 with Next year EPS estimates of -1.70. For the next quarter, that number is -0.40. This implies an EPS growth rate of -30.10% for this year and -3.70% for next year.

Float and Shares Shorts:

At present, 67.69 million GRCL shares are outstanding with a float of 51.86 million shares on hand for trading. On May 14, 2023, short shares totaled 0.31 million, which was 0.46% higher than short shares on Apr 13, 2023. In addition to Dr. Wei Cao BM, Ph.D. as the firm’s Founder, Chairman & CEO, Dr. Yili Xie M.B.A., Ph.D. serves as its Chief Financial Officer.

Institutional Ownership:

Through their ownership of 55.53% of GRCL’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 5.52% of GRCL, in contrast to 23.01% held by mutual funds. Shares owned by individuals account for –. As the largest shareholder in GRCL with 14.62% of the stake, Temasek Holdings Pte Ltd. holds 9,901,940 shares worth 9,901,940. A second-largest stockholder of GRCL, Great Point Partners LLC, holds 3,153,206 shares, controlling over 4.66% of the firm’s shares. Sphera Funds Management Ltd. is the third largest shareholder in GRCL, holding 2,360,580 shares or 3.49% stake. With a 1.97% stake in GRCL, the Emerging Markets Growth Fund Inc. is the largest stakeholder. A total of 1,336,443 shares are owned by the mutual fund manager. The Federated Hermes Kaufmann Fund, which owns about 1.00% of GRCL stock, is the second-largest Mutual Fund holder. It holds 679,512 shares valued at 1.18 million. Federated Hermes Kaufmann Small C holds 0.89% of the stake in GRCL, owning 600,338 shares worth 1.04 million.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2023, GRCL reported revenue of $0.00 and operating income of -$145.82M. The EBITDA in the recently reported quarter was -$141.32M and diluted EPS was -$2.35.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for GRCL since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With GRCL analysts setting a high price target of $20.00 and a low target of $7.00, the average target price over the next 12 months is $12.57. Based on these targets, GRCL could surge 657.58% to reach the target high and rise by 165.15% to reach the target low. Reaching the average price target will result in a growth of 376.14% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.